4105 Stock Overview
Engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
TTY Biopharm Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$72.70 |
| 52 Week High | NT$83.00 |
| 52 Week Low | NT$69.50 |
| Beta | 0.20 |
| 1 Month Change | -1.49% |
| 3 Month Change | -1.36% |
| 1 Year Change | -9.13% |
| 3 Year Change | 6.13% |
| 5 Year Change | -11.45% |
| Change since IPO | 1,101.50% |
Recent News & Updates
Recent updates
Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly
Apr 02
Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?
Mar 15Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?
Feb 25TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Feb 07TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially
Jan 19What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?
Jan 10
TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet
Dec 15How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?
Nov 25Shareholder Returns
| 4105 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -0.7% | -0.01% | -2.1% |
| 1Y | -9.1% | -2.7% | 25.6% |
Return vs Industry: 4105 underperformed the TW Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 4105 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 4105 volatility | |
|---|---|
| 4105 Average Weekly Movement | 1.1% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 4105 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4105's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | n/a | n/a | www.tty.com.tw |
TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business Unit, and Other Business Unit segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments.
TTY Biopharm Company Limited Fundamentals Summary
| 4105 fundamental statistics | |
|---|---|
| Market cap | NT$18.08b |
| Earnings (TTM) | NT$1.12b |
| Revenue (TTM) | NT$5.83b |
16.1x
P/E Ratio3.1x
P/S RatioIs 4105 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4105 income statement (TTM) | |
|---|---|
| Revenue | NT$5.83b |
| Cost of Revenue | NT$2.42b |
| Gross Profit | NT$3.41b |
| Other Expenses | NT$2.29b |
| Earnings | NT$1.12b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.50 |
| Gross Margin | 58.47% |
| Net Profit Margin | 19.22% |
| Debt/Equity Ratio | 33.0% |
How did 4105 perform over the long term?
See historical performance and comparisonDividends
4.8%
Current Dividend Yield78%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:35 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TTY Biopharm Company Limited is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Jerry Su | Credit Suisse |
| Christine Wang | Daiwa Securities Co. Ltd. |